🎉 M&A multiples are live!
Check it out!

Candel Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Candel Therapeutics and other public comps.

See Candel Therapeutics Valuation Multiples

Candel Therapeutics Overview

About Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.


Founded

2003

HQ

United States of America
Employees

42

Website

candeltx.com

Financials

LTM Revenue n/a

LTM EBITDA -$35.7M

EV

$385M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Candel Therapeutics Financials

Candel Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$35.7M.

In the most recent fiscal year, Candel Therapeutics achieved revenue of n/a and an EBITDA of -$34.4M.

Candel Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Candel Therapeutics valuation multiples based on analyst estimates

Candel Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $0.1M n/a n/a n/a XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$33.9M -$34.4M -$35.1M -$35.7M XXX
EBITDA Margin -27117% -Infinity% -Infinity% -Infinity% XXX
Net Profit -$36.1M -$18.8M -$37.9M XXX XXX
Net Margin -28899% -Infinity% -Infinity% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Candel Therapeutics Stock Performance

As of February 10, 2025, Candel Therapeutics's stock price is $9.

Candel Therapeutics has current market cap of $385M, and EV of $385M.

See Candel Therapeutics trading valuation data

Candel Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$385M $385M XXX XXX XXX XXX $-1.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Candel Therapeutics Valuation Multiples

As of February 10, 2025, Candel Therapeutics has market cap of $385M and EV of $385M.

Candel Therapeutics's trades at n/a LTM EV/Revenue multiple, and -10.8x LTM EBITDA.

Analysts estimate Candel Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Candel Therapeutics and 10K+ public comps

Candel Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $385M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -11.0x XXX XXX XXX
P/E -7.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Candel Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Candel Therapeutics Valuation Multiples

Candel Therapeutics's NTM/LTM revenue growth is n/a

Candel Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Candel Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Candel Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Candel Therapeutics and other 10K+ public comps

Candel Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 2% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Candel Therapeutics Public Comps

See valuation multiples for Candel Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Candel Therapeutics M&A and Investment Activity

Candel Therapeutics acquired  XXX companies to date.

Last acquisition by Candel Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Candel Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Candel Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Candel Therapeutics

When was Candel Therapeutics founded? Candel Therapeutics was founded in 2003.
Where is Candel Therapeutics headquartered? Candel Therapeutics is headquartered in United States of America.
How many employees does Candel Therapeutics have? As of today, Candel Therapeutics has 42 employees.
Who is the CEO of Candel Therapeutics? Candel Therapeutics's CEO is Dr. Paul Peter Tak, M.D.,PhD.
Is Candel Therapeutics publicy listed? Yes, Candel Therapeutics is a public company listed on NAS.
What is the stock symbol of Candel Therapeutics? Candel Therapeutics trades under CADL ticker.
When did Candel Therapeutics go public? Candel Therapeutics went public in 2021.
Who are competitors of Candel Therapeutics? Similar companies to Candel Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Candel Therapeutics? Candel Therapeutics's current market cap is $385M
What is the current EBITDA of Candel Therapeutics? Candel Therapeutics's last 12-month EBITDA is -$35.7M.
What is the current EV/EBITDA multiple of Candel Therapeutics? Current EBITDA multiple of Candel Therapeutics is -10.8x.
Is Candel Therapeutics profitable? Yes, Candel Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.